The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice
Open accessAbstract
Objective: Currently no effective disease‐modifying agents exist for the treatment of Alzheimer disease (AD). The Fyn tyrosine kinase is implicated in AD pathology triggered by amyloid‐ß oligomers (Aßo) and propagated by Tau. Thus, Fyn inhibition may prevent or delay disease progression. Here, we sought to repurpose the Src family kinase inhibitor oncology compound, AZD0530, for AD. Methods: The pharmacokinetics and distribution of AZD0530 were evaluated in mice. Inhibition of Aßo signaling to Fyn, Pyk2, and Glu receptors by AZD0530 was tested by brain slice assays. After AZD0530 or vehicle treatment of wild‐type and AD transgenic mice, memory was assessed by Morris water maze and novel object recognition. For these cohorts, amyloid precursor protein (APP) metabolism, synaptic markers (SV2 and PSD‐95), and targets of Fyn (Pyk2 and Tau) were studied by immunohistochemistry and by immunoblotting. Results: AZD0530 potently inhibits Fyn and prevents both Aßo‐induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2, and of NR2B Glu receptors in brain slices. After 4 weeks of treatment, AZD0530 dosing of APP/PS1 transgenic mice fully rescues spatial memory deficits and synaptic depletion, without altering APP or Aß metabolism. AZD0530 treatment also reduces microglial activation in APP/PS1 mice, and rescues Tau phosphorylation and deposition abnormalities in APP/PS1/Tau transgenic mice. There is no evidence of AZD0530 chronic toxicity. Interpretation: Targeting Fyn can reverse memory deficits found in AD mouse models, and rescue synapse density loss characteristic of the disease. Thus, AZD0530 is a promising candidate to test as a potential therapy for AD. Ann Neurol 2015;77:953–971
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This reciprocal regulation is further supported by the observation that Aβ-induced Fyn signalling is associated with downstream Pyk2 phosphorylation [68].”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [68]
In the citing paper
“the most common method to quantify synaptic density has been the quantification of pre-(e.g., synaptophysin [9], synapsin [8]) and post-synaptic (e.g., PSD-95 [10]) genes/proteins”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [10]
In the citing paper
“work from our group and others has shown that quantification of SV2A is similar to that of other markers of synaptic density in clinical samples and after drug challenge”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M. E., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 290
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–317 of 317
KILLMAR, J. T., Xue, Y., Wang, R., Rex, T. S., Khan, M. M., Liao, F., & McDonald, M. P. (2025) · Research Square · doi:10.21203/rs.3.rs-6465973/v1
Brody, A. H., Nies, S. H., Guan, F., Smith, L. M., Mukherjee, B., Salazar, S. A., Lee, S., Lam, T. K. T., & Strittmatter, S. M. (2022) · Figshare · doi:10.6084/m9.figshare.19695711
Self-citationGavilán, J., Panes-Fernández, J., Araya, A., Pérez-Manríquez, C., Becerra, J., Varas, P., Moraga‐Cid, G., Yévenes, G. E., & Fuentealba, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1725284 · Cited by 1
Research Progress on FAK in Neurological Diseases
赵, 璐. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162595
New roles of the Lyn tyrosine kinase in psoriasis development and cell death
Diaz, L. E. A. (2018) · theses.fr (ABES) · doi:10.70675/3deccde8zd3dez40abzbda2ze9b04bfdfd62
Boudet-Devaud, F. (2018) · theses.fr (ABES) · doi:10.70675/111341b9z5eeez4531z8f07zcb44d6f469a0
Arnould, H. (2019) · theses.fr (ABES) · doi:10.70675/9f070729z72aez4fccz9604z8c52be1a62e6
Pathophysiological role of Pyk2 in the nervous system
de Pins, B. (2019) · theses.fr (ABES) · doi:10.70675/e9fd4e35z9e7ez42d4za65cz5d999e5b2d5e
Ribeiro, L. W. (2023) · theses.fr (ABES) · doi:10.70675/68582d99z4406z4ad4zbd76z15927fb63da5
Chemical probes for Alzheimer’s disease targets
Aiken, S., Zarganes‐Tzitzikas, T., & Brennan, P. E. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260014
Zhang, K., Zheng, Y., Liu, X., Pan, J., Qi, H., Wang, A., Li, X., Wu, F., Shen, X., Liu, H., et al. (2026) · Environment International · doi:10.1016/j.envint.2026.110482
Wang, H., Fan, X., Ping, J., Shao, Q., Cai, W., Wang, H., Ji, Q., Su, M., & Qian, W. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00590-0
Yang, T., Tran, K. C., Leng, A., Langness, V. F., Massa, S. M., & Longo, F. M. (2026) · Cells · doi:10.3390/cells15191822
BindingDB Entry 50018884: Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
BindingDB (2024) · UC San Diego · doi:10.7270/q2d50s68
BindingDB (2020) · UC San Diego · doi:10.7270/q24170kg
Metadata
- Authors
- Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Department of Psychiatry Yale University School of Medicine New Haven CT
- Corresponding author
- Strittmatter, Stephen M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2015-03-21
- Volume
- 77
- Issue
- 6
- Pages
- 953-971
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC4447598
- OpenAlex
- W1725757145
- Cited by
- 314
- References
- 62
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 19 · 2023: 25 · 2022: 28 · 2021: 38 · 2020: 41 · 2019: 28 · 2018: 40 · 2017: 29 · 2016: 24 · 2015: 13
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UH3-TR000967, R01AG034924)
- BrightFocus Foundation
- Alzheimer's Association
- Falk Medical Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, Fyn tyrosine kinase, AZD0530, Src family kinase inhibitor, amyloid-beta oligomers, Pyk2, NMDA receptor NR2B, APP/PS1 mice, spatial memory impairment, synaptic loss, PSD-95, microglial activation, tau phosphorylation, drug repurposing, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Behavior, Animal, Disease Models, Animal, Mice, Inbred C57BL, Mice, Transgenic, Quinazolines, Signal Transduction, Amyloid beta-Peptides, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-fyn, Mice, Focal Adhesion Kinase 2, Benzodioxoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
